Edinburgh spin-out BioCaptiva names new non-exec chair 2026

Key Points

• University of Edinburgh spinout BioCaptiva has named Stephane Argivier as its non-executive chair.
• This is amid the firm’s efforts to drive global expansion in the liquid biopsy space for cancer.
• Mr Argivier joins the firm with 30 years’ experience in the areas of life science tools, diagnostics, and IVD raw materials.
• BioCaptiva’s CEO Jeremy Wheeler has stated that Frank Armstrong’s leadership helped develop the firm into a commercial entity.
• The firm recently secured £1.58 million in March 2026 as well as introduced its msX magnetic bead technology to the US market.
• Its technology seeks to enhance the process of sample preparation for liquid biopsy through improved capture of cell free DNA.

Edinburgh (Edinburgh Daily ) August 12, 2026 – A University of Edinburgh spin-out has appointed a new chair to steer its global growth in the cancer liquid biopsy market. BioCaptiva has named seasoned life sciences executive Stephane Argivier as non-executive chairman, as it moves to scale its proprietary msX polymer platform for capturing cell-free DNA (cfDNA) from blood and other biofluids. The appointment follows a period of rapid development for the company, which secured £1.58 million in seed funding earlier this year and began commercialising its magnetic bead extraction kits in the United States.

What has BioCaptiva announced about its new chair?

BioCaptiva has confirmed that Stephane Argivier will take on the role of non-executive chairman to help guide its next phase of international expansion. According to the company’s own board biographies, Argivier is a life sciences executive and board adviser with three decades of experience across enabling tools, diagnostics and critical in vitro diagnostics (IVD) raw materials. His career includes executive and non-executive positions at firms including SCIPAC, BBI Solutions, MIP Discovery and Logical Biological, where he worked on commercial strategy, product industrialisation and strategic partnerships.

As reported by journalists covering the announcement, chief executive Jeremy Wheeler said: “Frank’s leadership helped transform BIOCAPTIVA from an innovative technology company into a commercially ready business, and we are extremely grateful for his contribution.” Wheeler’s statement acknowledges the role of Dr Frank Armstrong, who had previously served as non-executive chairman and was appointed to the board in 2021, according to Companies House records.

Who is Stephane Argivier and what is his background?

Stephane Argivier is described by BioCaptiva as a seasoned life sciences executive with 30 years’ experience across life science enabling tools, diagnostics and critical IVD raw materials. He has worked with both privately owned and venture capital-backed organisations, supporting them through fundraising, international growth, operational scale-up and strategic exits.

His track record includes building and scaling businesses, leading global commercial and cross-functional teams, and advising boards on governance and leadership development. BioCaptiva states that Argivier brings experience in turning differentiated science into scalable commercial businesses, securing investment and building long-term shareholder value.

What is BioCaptiva’s technology and why does it matter?

BioCaptiva was spun out of the University of Edinburgh in 2021 and is developing technologies to extract cell-free DNA more efficiently from blood samples for use in cancer research and diagnostics. Its msX platform uses proprietary polymer coatings and magnetic beads to capture cfDNA directly from whole blood without the need for centrifugation or chemical lysis.

The company says its approach addresses a long-standing bottleneck in liquid biopsy: the pre-analytical step of sample preparation. By improving analyte recovery, reducing contamination and preserving sample integrity at room temperature, BioCaptiva aims to enable more sensitive and reproducible downstream sequencing and testing.

In March 2026, BioCaptiva announced it had raised £1.58 million and launched its first product in the US, bringing its magnetic bead technology to one of the world’s largest research markets. The funding round included support from Archangels and other investors, according to coverage at the time.

How has BioCaptiva’s leadership team evolved?

Alongside the appointment of Argivier as chair, BioCaptiva has strengthened its senior team over the past year. Alan Schafer was appointed chief technology officer, bringing more than 30 years’ experience in genetics technologies and molecular diagnostics. Schafer previously served as CTO at Inivata, a liquid biopsy company acquired by NeoGenomics in 2021 for $415 million, and held CEO roles at Population Genetics Technologies and 14M Genomics.

Alison Williamson serves as chief financial officer and board director, having joined after a career that included CFO roles at DYSIS Medical and Aircraft Medical, the latter acquired by Medtronic for $112 million. Stephen Little, a serial biotechnology entrepreneur who led DxS to its £85 million exit to QIAGEN in 2009, sits on the board as investor director.

What is the outlook for the liquid biopsy market?

The global liquid biopsy market is projected to grow from an estimated USD 9.49 billion in 2026 to USD 33.45 billion by 2035, representing a compound annual growth rate of 15 per cent, according to industry reports. Growth is being driven by demand for precision oncology, improvements in sequencing technologies and increasing clinical use of circulating biomarkers for cancer detection and monitoring.

Next-generation sequencing is expected to account for around 53 per cent of the liquid biopsy market in 2026 and expand at a CAGR of 17.1 per cent through 2035. Companies that can improve the reliability and scalability of sample preparation stand to benefit as more laboratories and diagnostic firms adopt liquid biopsy workflows.

Background: How did BioCaptiva develop from University of Edinburgh research?

BioCaptiva’s technology is rooted in more than a decade of research at the University of Edinburgh, led by Professor Tim Aitman, director of the Centre for Genomic and Experimental Medicine, and Professor Mark Bradley of the School of Chemistry. The company was formally spun out in 2021 to commercialise its BioCaptis device and related msX polymer platform for cfDNA capture.

Early coverage in 2021 highlighted that the BioCollector device could capture circulating free DNA from blood in greater quantities than standard single blood draws, overcoming a significant limitation of existing liquid biopsy testing. Since then, the company has progressed from research and development to raising seed capital, appointing a full executive team and beginning product launches in key markets such as the US.

Prediction: How could this appointment affect researchers, diagnostics firms and investors?

Argivier’s appointment is likely to be most consequential for three groups: cancer researchers and laboratory scientists, diagnostics and OEM companies, and early-stage life sciences investors. For researchers, a chair with deep experience in scaling life sciences tools could help BioCaptiva refine its msX kits and integrate more smoothly with automated workflows, potentially improving data quality and throughput in multi-site trials and biobanking.

For diagnostics firms and OEMs, a more commercially mature BioCaptiva may offer more reliable supply, clearer regulatory pathways and stronger technical support as they evaluate pre-analytical solutions for their own liquid biopsy assays. For investors, the combination of a seasoned chair, an experienced executive team and a growing market could make BioCaptiva a more attractive candidate for follow-on funding or strategic partnerships, particularly if the company can demonstrate clinical utility and cost advantages over existing sample preparation methods.